Schwartz GG, et al. - Researchers intended to confirm if proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition decreases the risk of peripheral artery disease (PAD) events or venous thromboembolism (VTE) following acute coronary syndrome (ACS), and whether such effects are associated with levels of lipoprotein(a) or LDL-C in this prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial, which was performed in overall 18,924 patients having recent ACS on intensive or maximum-tolerated statin therapy who were randomly assigned to the PCSK9 inhibitor alirocumab or placebo. The evaluation of PAD events (critical limb ischemia, limb revascularization, or amputation for ischemia) and VTE (deep vein thrombosis or pulmonary embolism) was done in a prespecified analysis. According to the findings, in statin-treated patients with recent ACS, the risk of PAD events was found to be associated with lipoprotein(a) level and was shown to be decreased by alirocumab, especially in those with high lipoprotein(a). There is a need for further investigation in order to corroborate if risk of VTE is associated with lipoprotein(a) level and its reduction with alirocumab.